José Antonio Mata Marín is the lead sponsor of 3 current clinical trials in our Mexico register. 3 are recruiting patients now. The most common phase is Phase 4. The drugs named most often in its trials are Dolutegravir/Lamivudine, BIC/FTC/TAF and DOR/3TC/TDF. The most-studied condition is HIV Infections.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up
NCT07138144 · ClinicalTrials.gov ↗ · HIV Infections
Drug: Dolutegravir/Lamivudine |
Phase 4 | Recruiting | 2025-07 | Mexico |
|
DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity
NCT07075146 · ClinicalTrials.gov ↗ · HIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity
Drugs: BIC/FTC/TAF, DOR/3TC/TDF |
Phase 3 | Recruiting | 2025-05 | Mexico |
|
Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in Mexico
NCT06907056 · ClinicalTrials.gov ↗ · HIV Infection
Drug: Dolutegravir/Lamivudine |
Phase 4 | Recruiting | 2023-11 | Mexico |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Mexico | 3 | 3 |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
José Antonio Mata Marín is the lead sponsor of 3 current trials on ClinicalTrials.gov in our Mexico register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 3 drugs and biologicals as interventions. The most frequent are Dolutegravir/Lamivudine (2), BIC/FTC/TAF (1) and DOR/3TC/TDF (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.